Quantitative phosphoproteomics of proteasome inhibition in multiple myeloma cells.

• Published in: PLoS ONE
• Main Authors: Feng Ge, Chuan-Le Xiao, Li-Jun Bi, Sheng-Ce Tao, Sheng Xiong, Xin-Feng Yin, Li-Ping Li, Chun-Hua Lu, Hai-Tao Jia, Qing-Yu He
• Format: Article
• Language: English
• Published: Public Library of Science (PLoS) 2010-09-01
• Online Access: https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20927383/?tool=EBI

The proteasome inhibitor bortezomib represents an important advance in the treatment of multiple myeloma (MM). Bortezomib inhibits the activity of the 26S proteasome and induces cell death in a variety of tumor cells; however, the mechanism of cytotoxicity is not well understood. We investigated the differential phosphoproteome upon proteasome inhibition by using stable isotope labeling by amino acids in cell culture (SILAC) in combination with phosphoprotein enrichment and LC-MS/MS analysis. In total 233 phosphoproteins were identified and 72 phosphoproteins showed a 1.5-fold or greater change upon bortezomib treatment. The phosphoproteins with expression alterations encompass all major protein classes, including a large number of nucleic acid binding proteins. Site-specific phosphopeptide quantitation revealed that Ser38 phosphorylation on stathmin increased upon bortezomib treatment, suggesting new mechanisms associated to bortezomib-induced apoptosis in MM cells. Further studies demonstrated that stathmin phosphorylation profile was modified in response to bortezomib treatment and the regulation of stathmin by phosphorylation at specific Ser/Thr residues participated in the cellular response induced by bortezomib. Our systematic profiling of phosphorylation changes in response to bortezomib treatment not only advanced the global mechanistic understanding of the action of bortezomib on myeloma cells but also identified previously uncharacterized signaling proteins in myeloma cells.